Dosage forms containing apomorphine for ameliorating male erectile dysfunction
US6200983A · kind A · utility
17Cited by
9References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 15, 1999 |
| Grant date | Mar 13, 2001 |
| Priority date | — |
| Expiry date | Nov 15, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.